These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35294956)

  • 1. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis.
    Dong J; Ni J; Chen J; Wang X; Ye L; Xu X; Guo W; Chen X
    J Ovarian Res; 2024 Jun; 17(1):133. PubMed ID: 38937827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
    Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
    Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
    PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
    Heilmann AM; Riess JW; McLaughlin-Drubin M; Huang RSP; Hjulstrom M; Creeden J; Alexander BM; Erlich RL
    Oncologist; 2024 Feb; 29(2):e224-e236. PubMed ID: 37682776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors.
    Verner EL; Jackson JB; Severson E; Valkenburg KC; Greer AE; Riley DR; Sausen M; Maddox C; McGregor PM; Karandikar A; Hastings SB; Previs RA; Reddy VP; Jensen TJ; Ramkissoon SH
    J Mol Diagn; 2023 Jul; 25(7):477-489. PubMed ID: 37068734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
    Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
    Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
    [No Abstract]   [Full Text] [Related]  

  • 8. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
    Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
    PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach for improvement of the accuracy of cancer gene panel testing.
    Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
    Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.
    Lin DI; Huang RSP; Ladas I; Keller RB; Patel NR; Lakis S; Decker B; Janovitz T; Mata DA; Ross JS; Vergilio JA; Elvin JA; Herbst RS; Mack PC; Killian JK
    Front Oncol; 2024; 14():1328512. PubMed ID: 38444675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
    Akolkar D; Patil D; Srivastava N; Patil R; Datta V; Apurwa S; Yashwante N; Dhasarathan R; Gosavi R; John J; Khan S; Jadhav N; Mene P; Ahire D; Pawar S; Bodke H; Sahoo S; Nile A; Saindane D; Darokar H; Devhare P; Srinivasan A; Datar R
    PLoS One; 2021; 16(2):e0246048. PubMed ID: 33556149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test.
    Ferguson S; Sriram S; Wallace JK; Lee J; Kim JA; Lee Y; Oh BB; Lee WC; Lee S; Connolly-Strong E
    Cancer Invest; 2024 May; 42(5):390-399. PubMed ID: 38773925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
    Ido M; Fujii K; Mishima H; Kubo A; Saito M; Banno H; Ito Y; Goto M; Ando T; Mouri Y; Kousaka J; Imai T; Nakano S
    BMC Cancer; 2024 Jan; 24(1):85. PubMed ID: 38229073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
    Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
    Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
    BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
    Chung JH; Dewal N; Sokol E; Mathew P; Whitehead R; Millis SZ; Frampton GM; Bratslavsky G; Pal SK; Lee RJ; Necchi A; Gregg JP; Lara P; Antonarakis ES; Miller VA; Ross JS; Ali SM; Agarwal N
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31218271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling for oncological advancements by precision medicine.
    Pankiw M; Brezden-Masley C; Charames GS
    Med Oncol; 2023 Nov; 41(1):1. PubMed ID: 37993657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
    Zollinger DR; Rivers E; Fine A; Huang Y; Son J; Kalyan A; Gray W; Baharian G; Hammond C; Ram R; Ringman L; Hafez D; Savel D; Patel V; Dantone M; Guo C; Childress M; Xu C; Johng D; Wallden B; Pokharel P; Camara W; Hegde PS; Hughes J; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Powles T; Ferree S; Dennis L; Young A
    PLoS One; 2024; 19(5):e0302129. PubMed ID: 38753705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
    Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
    ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.